|
Quotes & Info
|
| ZIOP > SEC Filings for ZIOP > Form 8-K on 12-Feb-2013 | All Recent SEC Filings |
12-Feb-2013
Other Events, Financial Statements and Exhibits
ZIOPHARM Oncology, Inc., or the Company, announced today that the Phase 3 trial
of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma(PICASSO
3) has reached its target number of progression-free survival (PFS) events, and
that top line data from PICASSO 3 will be announced by the Company during the
last week of March 2013.
A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.
(d) Exhibits
Exhibit No. Description
99.1 Press release of the Company dated February 12, 2013
|
|